- Home
- CWK vs KNSA Comparison
CWK vs KNSA Comparison
Compare CWK & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWK | KNSA |
|---|---|---|
| Founded | 1784 | 2015 |
| Country | United States | United Kingdom |
| Employees | 53000 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CWK | KNSA |
|---|---|---|
| Price | $13.23 | $47.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $17.64 | ★ $55.29 |
| AVG Volume (30 Days) | ★ 1.5M | 565.9K |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | 0.38 | ★ 0.75 |
| Revenue | ★ $10,288,200,000.00 | $677,564,000.00 |
| Revenue This Year | $6.93 | $38.01 |
| Revenue Next Year | $6.38 | $17.42 |
| P/E Ratio | ★ $34.63 | $63.27 |
| Revenue Growth | 8.91 | ★ 60.09 |
| 52 Week Low | $7.82 | $19.42 |
| 52 Week High | $17.40 | $50.03 |
Technical Indicators
Market Signals| Indicator | CWK | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 51.17 |
| Support Level | $11.62 | $39.96 |
| Resistance Level | $17.25 | $48.14 |
| Average True Range (ATR) | 0.52 | 1.83 |
| MACD | 0.22 | -0.03 |
| Stochastic Oscillator | 73.67 | 45.20 |
Price Performance
Historical ComparisonAbout CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such as valuation, project management, and facilities management.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.